[go: up one dir, main page]

DE60003550D1 - Substituierte 3-pyridyl-4-arylpyrrole und deren einsatz in verfahren zur therapeutischen und prophylaktischen behandlung - Google Patents

Substituierte 3-pyridyl-4-arylpyrrole und deren einsatz in verfahren zur therapeutischen und prophylaktischen behandlung

Info

Publication number
DE60003550D1
DE60003550D1 DE60003550T DE60003550T DE60003550D1 DE 60003550 D1 DE60003550 D1 DE 60003550D1 DE 60003550 T DE60003550 T DE 60003550T DE 60003550 T DE60003550 T DE 60003550T DE 60003550 D1 DE60003550 D1 DE 60003550D1
Authority
DE
Germany
Prior art keywords
arylpyrrole
pyridyl
therapeutic
substituted
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60003550T
Other languages
English (en)
Other versions
DE60003550T2 (de
Inventor
James Bullington
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceuticals Inc
Original Assignee
Ortho McNeil Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho McNeil Pharmaceutical Inc filed Critical Ortho McNeil Pharmaceutical Inc
Application granted granted Critical
Publication of DE60003550D1 publication Critical patent/DE60003550D1/de
Publication of DE60003550T2 publication Critical patent/DE60003550T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Psychiatry (AREA)
  • AIDS & HIV (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
DE60003550T 1999-05-14 2000-04-28 Substituierte 3-pyridyl-4-arylpyrrole und deren einsatz in verfahren zur therapeutischen und prophylaktischen behandlung Expired - Fee Related DE60003550T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13413999P 1999-05-14 1999-05-14
US134139P 1999-05-14
PCT/US2000/011531 WO2000069847A1 (en) 1999-05-14 2000-04-28 Substituted 3-pyridyl-4-arylpyrroles, and related therapeutic and prophylactic methods

Publications (2)

Publication Number Publication Date
DE60003550D1 true DE60003550D1 (de) 2003-07-31
DE60003550T2 DE60003550T2 (de) 2004-04-15

Family

ID=22461942

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60003550T Expired - Fee Related DE60003550T2 (de) 1999-05-14 2000-04-28 Substituierte 3-pyridyl-4-arylpyrrole und deren einsatz in verfahren zur therapeutischen und prophylaktischen behandlung

Country Status (23)

Country Link
US (1) US6562843B1 (de)
EP (1) EP1178981B1 (de)
JP (1) JP2002544272A (de)
KR (1) KR20010114267A (de)
CN (1) CN1210273C (de)
AR (1) AR023986A1 (de)
AT (1) ATE243690T1 (de)
AU (1) AU777702B2 (de)
BR (1) BR0010560A (de)
CA (1) CA2374559A1 (de)
DE (1) DE60003550T2 (de)
DK (1) DK1178981T3 (de)
ES (1) ES2200878T3 (de)
HK (1) HK1042901B (de)
IL (1) IL146465A0 (de)
MX (1) MXPA01011720A (de)
MY (1) MY127675A (de)
NZ (1) NZ515531A (de)
PT (1) PT1178981E (de)
RU (1) RU2238940C2 (de)
TW (1) TWI229671B (de)
WO (1) WO2000069847A1 (de)
ZA (1) ZA200110271B (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7122666B2 (en) 1999-07-21 2006-10-17 Sankyo Company, Limited Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses
GB0102672D0 (en) * 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
WO2003022832A1 (en) * 2001-09-05 2003-03-20 Smithkline Beecham P.L.C. Pyridylfurans and pyrroles as raf kinase inhibitors
WO2004029040A1 (en) * 2002-09-27 2004-04-08 Janssen Pharmaceutica N.V. 3,4-disubstituted pyrroles and their for use in treating inflammatory diseases
DE602004024374D1 (de) * 2003-03-13 2010-01-14 Vertex Pharma Zusammensetzungen zur verwendung als protein-kinase-inhibitoren
EP1628957B1 (de) * 2003-05-26 2010-09-29 Takeda Pharmaceutical Company Limited Sulfopyrrolderivate
AU2004251681A1 (en) * 2003-06-06 2005-01-06 The Trustees Of The University Of Pennsylvania P38 kinase inhibitor compositions and methods of use
ES2897422T3 (es) * 2004-05-14 2022-03-01 Vertex Pharma Compuestos pirroles como inhibidores de proteínas cinasas ERK y composiciones farmacéuticas que contienen esos compuestos
US7531560B2 (en) * 2004-11-10 2009-05-12 Boehringer Ingelheim Pharmaceuticals, Inc. Anti-cytokine heterocyclic compounds
WO2007139781A2 (en) * 2006-05-23 2007-12-06 Cree Led Lighting Solutions, Inc. Lighting device

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3994890A (en) 1974-01-31 1976-11-30 Chugai Seiyaku Kabushiki Kaisha 1-Aminoalkyl, 3-phenyl indazoles
JPH0615542B2 (ja) 1986-07-22 1994-03-02 吉富製薬株式会社 ピラゾロピリジン化合物
MX9300141A (es) 1992-01-13 1994-07-29 Smithkline Beecham Corp Compuestos de imidazol novedosos, procedimiento para su preparacion y composiciones farmaceuticas que lo contienen.
JPH11510511A (ja) * 1995-08-10 1999-09-14 メルク エンド カンパニー インコーポレーテッド ２，５−置換アリールピロール、この化合物を含有する組成物及び使用方法
CA2228136A1 (en) * 1995-08-10 1997-02-20 Merck & Co., Inc. 2-substituted aryl pyrroles, compositions containing such compounds and methods of use
WO1997016442A1 (en) 1995-10-31 1997-05-09 Merck & Co., Inc. Substituted pyridyl pyrroles, compositions containing such compounds and methods of use
WO1998002430A1 (en) * 1996-07-11 1998-01-22 Pfizer Pharmaceuticals Inc. Pyridylpyrrole compounds useful as interleukin- and tnf antagonists
US5776954A (en) 1996-10-30 1998-07-07 Merck & Co., Inc. Substituted pyridyl pyrroles, compositions containing such compounds and methods of use

Also Published As

Publication number Publication date
CN1361773A (zh) 2002-07-31
RU2238940C2 (ru) 2004-10-27
HK1042901A1 (en) 2002-08-30
AU4677700A (en) 2000-12-05
AR023986A1 (es) 2002-09-04
MY127675A (en) 2006-12-29
IL146465A0 (en) 2002-07-25
CN1210273C (zh) 2005-07-13
US6562843B1 (en) 2003-05-13
ES2200878T3 (es) 2004-03-16
MXPA01011720A (es) 2003-10-14
DE60003550T2 (de) 2004-04-15
WO2000069847A1 (en) 2000-11-23
NZ515531A (en) 2004-03-26
KR20010114267A (ko) 2001-12-31
PT1178981E (pt) 2003-11-28
BR0010560A (pt) 2002-06-04
ZA200110271B (en) 2003-05-28
EP1178981B1 (de) 2003-06-25
DK1178981T3 (da) 2003-09-29
HK1042901B (en) 2003-11-07
CA2374559A1 (en) 2000-11-23
AU777702B2 (en) 2004-10-28
JP2002544272A (ja) 2002-12-24
TWI229671B (en) 2005-03-21
ATE243690T1 (de) 2003-07-15
EP1178981A1 (de) 2002-02-13

Similar Documents

Publication Publication Date Title
DE60020102D1 (de) Haarbehandlungsgerät und verfahren
DE60023128D1 (de) Pyrazolecarboxamide zur behandlung von fettleibigkeit und anderen erkrankungen
EE200100480A (et) Ksenoon kasutamiseks närvimürgistuste ravis
DE60006691D1 (de) Kontaktkörper und verfahren und vorrichtung zur deren herstellung
DE69825447D1 (de) Gerät zur dermatologischen behandlung
GB0109414D0 (en) Well treatment fluids and methods for the use thereof
EP1200086A4 (de) Methoden zur behandlung oder vorbeugung von schmerzen und angstzuständen
DE69941497D1 (de) Schäumende Zusammensetzung zur Haarreinigung und Haarbehandlung
DE60012138D1 (de) Gerät zur behandlung von fibrillation
PT946175E (pt) Utilizacao de uma combinacao de inibidores de h+, k+ -atpase e de glucocorticiodes no tratamento de polipos nasais
EP1506001A4 (de) Verfahren und zusammensetzungen zur behandlung von epithelläsionen in vagina, zervix und uterus
DE60036899D1 (de) Chemikalie und verfahren zur wasserbehandlung
DE60003550D1 (de) Substituierte 3-pyridyl-4-arylpyrrole und deren einsatz in verfahren zur therapeutischen und prophylaktischen behandlung
DE19883021T1 (de) Entladungsoberflächenbehandlungsgerät und Entladungsoberflächenbehandlungsverfahren
DE50004446D1 (de) Verfahren und vorrichtung zur vergleichmässigung des energieeintrags in gargut
DE60027429D1 (de) Dihydrobenzodiazepinen und deren verwendung zur behandlung von dyslipidämien
AU2001265186A1 (en) Use of epoxyeicosatrienoic acids in the treatment of cerebrovascular conditions
PT932400E (pt) Derivados de anticonvulsionantes uteis no tratamento da dor neuropatica
DE60128427D1 (de) Verfahren und Einrichtungen zur elekrochemischen Behandlung eines Artikels
GB9919482D0 (en) Waste treatment apparatus and methods
GB2361644B (en) Waste treatment apparatus and methods
DE69932577D1 (de) Stangenbehandlungsgerät und Stangenladegerät
EP1173751A4 (de) Röntgendiffraktometer und verfahren
NO20022990D0 (no) Fremgangsmåte og sammensetning for behandling av smerte
DE19983932T1 (de) Erodierverfahren und Erodiereinrichtung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: BOEHMERT & BOEHMERT, 28209 BREMEN

8339 Ceased/non-payment of the annual fee